ADVACEF 250mg Injection/Powder for

What is ADVACEF 250mg

ADVACEF 250mg is a sterile injectable antibiotic formulation containing ceftriaxone sodium as its active ingredient. It is supplied as a dry powder in a single glass vial, intended for reconstitution before intravenous or intramuscular administration. Ceftriaxone belongs to the class of third-generation cephalosporins, a type of beta-lactam antibiotic known for its broad-spectrum activity against many gram-positive and gram-negative bacteria.

• Indications: ADVACEF 250mg is commonly prescribed to treat a variety of bacterial infections such as respiratory tract infections (including pneumonia), urinary tract infections, skin and soft tissue infections, septicemia, bone and joint infections, and meningitis.
• Broad-spectrum activity: Effective against many pathogens including Streptococcus species, Staphylococcus aureus (excluding MRSA), Escherichia coli, Klebsiella species, and Neisseria gonorrhoeae.
• Formulation: The dry powder formulation ensures stability and allows it to be stored easily before reconstitution with an appropriate diluent such as sterile water for injection or saline.
• Usage: Administered by healthcare professionals via intramuscular or intravenous injection to ensure rapid and effective therapeutic levels in the bloodstream.
• Therapeutic benefits: Ceftriaxone’s long half-life allows once or twice daily dosing, improving patient compliance and reducing hospital stays.

In summary, ADVACEF 250mg serves as a vital antibiotic option in managing moderate to severe bacterial infections, especially when oral therapy is not suitable or rapid systemic effect is required.

How to use ADVACEF 250mg

ADVACEF 250mg should be used strictly under the guidance of a qualified healthcare professional. It requires careful preparation and administration to ensure safety and efficacy.

• Reconstitution: The dry powder in the vial must be reconstituted with an appropriate sterile diluent, such as sterile water for injection or 0.9% sodium chloride solution, following manufacturer’s instructions. Use aseptic technique to avoid contamination.
• Route of administration: The reconstituted solution can be given either intramuscularly (IM) or intravenously (IV). IM injections are usually given deep into a large muscle such as the gluteus maximus. IV administration can be via slow injection or infusion.
• Dosing schedule: Dosage frequency depends on the infection severity and patient factors. Typically, once or twice daily dosing is used. Follow prescribed instructions carefully.
• Preparation of IV infusion: If administered IV, further dilution into an appropriate volume of intravenous fluids (such as 50-100 ml of saline or dextrose solution) is required, administered over 30 minutes to reduce vein irritation.
• Duration of therapy: The duration varies depending on the type and severity of infection. Common courses range from 5 to 14 days but may be longer for complicated infections.
• Monitoring: Patients should be monitored for therapeutic response and potential adverse effects. Renal and liver function tests might be needed during prolonged therapy.

Always inform your healthcare provider about any allergies, other medications, or underlying health conditions before starting ADVACEF 250mg. Do not self-administer this medication.

Mode of Action ADVACEF 250mg

ADVACEF 250mg contains ceftriaxone, a third-generation cephalosporin antibiotic. Its bactericidal effect stems from its ability to disrupt bacterial cell wall synthesis, which is crucial for bacterial survival and replication.

• Inhibition of cell wall synthesis: Ceftriaxone binds to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. PBPs are enzymes responsible for cross-linking the peptidoglycan layers that provide structural integrity to the bacterial cell wall.
• Interference with peptidoglycan cross-linking: By binding to PBPs, ceftriaxone prevents the formation of cross-links in the peptidoglycan structure, weakening the cell wall.
• Cell lysis and death: The weakened cell wall becomes unable to withstand osmotic pressure, causing the bacterial cell to lyse and die.
• Broad-spectrum activity: Ceftriaxone is effective against a wide range of gram-negative and some gram-positive bacteria due to its enhanced stability against many beta-lactamases (enzymes produced by bacteria that typically degrade beta-lactam antibiotics).
• Long half-life: Its prolonged half-life allows for convenient once or twice daily dosing, maintaining effective plasma concentrations over time.

In summary, ADVACEF 250mg acts by compromising bacterial cell wall integrity, leading to the elimination of pathogenic bacteria responsible for infections. It is ineffective against infections caused by bacteria lacking a cell wall or those resistant to beta-lactams.

ADVACEF 250mg Interactions ADVACEF 250mg

ADVACEF 250mg (ceftriaxone sodium) can interact with several medications, potentially altering its effectiveness or increasing the risk of adverse effects. It is critical to review all concomitant drugs before initiating therapy.

• Calcium-containing solutions: Ceftriaxone can form precipitates when mixed with calcium-containing IV fluids or solutions (such as Ringer’s lactate), leading to serious adverse events including embolism, especially in neonates and infants. Avoid simultaneous administration.
• Warfarin and other anticoagulants: Ceftriaxone may enhance the anticoagulant effect of warfarin, increasing bleeding risk. Monitoring of coagulation parameters (e.g., INR) is advised during concurrent use.
• Loop diuretics (e.g., furosemide): Increased risk of nephrotoxicity may occur when used together with ceftriaxone.
• Nephrotoxic agents: Concomitant use with other nephrotoxic drugs (such as aminoglycosides or vancomycin) may increase the risk of kidney damage; monitor renal function closely.
• Probenecid: May reduce renal tubular secretion of ceftriaxone, leading to higher plasma levels and prolonged effects.
• Oral contraceptives: Antibiotics including ceftriaxone may reduce the effectiveness of hormonal contraceptives; additional contraceptive methods should be considered.
• Live vaccines: Ceftriaxone may diminish the efficacy of live bacterial vaccines such as typhoid vaccine.

Always inform your healthcare provider about all medications, supplements, or herbal products you are taking to avoid potential drug interactions with ADVACEF 250mg.

Dosage of ADVACEF 250mg

The dosage of ADVACEF 250mg depends on the type and severity of infection, patient age, weight, and renal function. Below are general dosing guidelines; specific regimens should be individualized by a healthcare professional.

• Adults: For most infections, 1 to 2 grams of ceftriaxone once daily is common. In less severe infections, 250 mg to 500 mg once daily may be sufficient.
• Severe infections: Higher doses, such as 2 grams once daily or divided doses (1 gram every 12 hours), may be required for serious infections like meningitis or sepsis.
• Children: Typical dosing is 50 to 75 mg/kg/day, given once or twice daily. Maximum daily dose should not exceed 2 grams.
• Renal impairment: Ceftriaxone is excreted by both renal and biliary routes. Generally, dose adjustment is not necessary in mild to moderate renal impairment. However, in severe hepatic or renal dysfunction, caution is advised.
• Duration of treatment: Depends on infection type; usually ranges from 5 to 14 days but can be extended based on clinical response.

Always follow the prescribed dosing regimen provided by your healthcare provider. Do not alter doses or discontinue therapy without consulting a medical professional.

Possible side effects of ADVACEF 250mg

Like all medications, ADVACEF 250mg may cause side effects, though not everyone experiences them. Monitoring and prompt reporting of any adverse reactions is essential for patient safety.

• Common side effects:
  • Injection site reactions such as pain, swelling, or redness
  • Diarrhea or loose stools
  • Rash or mild allergic reactions including itching
  • Nausea and vomiting
• Less common but serious side effects:
  • Severe allergic reactions (anaphylaxis) presenting with difficulty breathing, swelling of face/lips/tongue, and hives
  • Clostridioides difficile-associated diarrhea (severe persistent diarrhea)
  • Hemolytic anemia or blood disorders (e.g., thrombocytopenia, leukopenia)
  • Elevated liver enzymes indicating liver irritation or damage
  • Kidney dysfunction signs such as decreased urine output or swelling
  • Superinfection with resistant organisms including fungal infections
• Other possible effects:
  • Headache or dizziness
  • Changes in taste
  • Joint pain or muscle aches

Seek immediate medical attention if you experience symptoms of a severe allergic reaction or persistent diarrhea. Inform your healthcare provider about any unusual symptoms during or after treatment with ADVACEF 250mg.

ADVACEF 250mg Contraindications ADVACEF 250mg

ADVACEF 250mg should not be used in the following conditions to avoid serious adverse effects or therapeutic failure:

• Hypersensitivity: Patients with a known allergy to ceftriaxone, other cephalosporins, penicillins, or beta-lactam antibiotics should not use ADVACEF 250mg due to potential for severe allergic reactions.
• Neonates (≤ 28 days) requiring calcium-containing IV fluids: The concomitant use of ceftriaxone with calcium-containing solutions is contraindicated due to risk of fatal precipitates in the lungs and kidneys.
• Severe liver disease: Use with caution or avoid in patients with significant hepatic impairment, especially if combined with renal dysfunction.
• Infections caused by ceftriaxone-resistant bacteria: Ineffective treatment may occur if pathogens produce beta-lactamases that ceftriaxone cannot inactivate.

Always inform your healthcare provider about any previous allergic reactions or medical conditions before starting ADVACEF 250mg.

Storage of ADVACEF 250mg

Proper storage of ADVACEF 250mg is crucial to maintain its potency and safety until use.

• Storage conditions: Store the dry powder vial at room temperature, typically between 20°C to 25°C (68°F to 77°F). Avoid excessive heat or freezing.
• Protect from moisture: Keep the vial in its original packaging to protect it from moisture and light exposure which can degrade the product.
• After reconstitution: Once reconstituted with a suitable diluent, the solution should be used promptly. If not used immediately, follow the manufacturer’s guidelines on stability and refrigeration. Usually, solutions should be used within 24 hours if refrigerated.
• Keep out of reach of children: To prevent accidental ingestion or misuse, store the medicine in a secure location away from children and pets.
• Disposal: Dispose of any unused or expired medication in accordance with local regulations to prevent environmental contamination and accidental exposure.

Always check the vial and packaging for expiry dates before use, and do not use the medicine beyond its expiration date.